NUT carcinoma (NC) shows very aggressive clinical behavior, occurs predominantly in the thorax and head and neck region of children and adults, and is defined by the presence of NUT (aka NUTM1) rearrangement, mostly BRD4-NUTM1 fusion resulting from t(15;19)(q13; p13.1). Socalled "NUT variants" harbor alternate fusions between NUTM1 and BRD3, NSD3, ZNF532, or unknown partners. Rare cases of pediatric tumors with CIC-NUTM1 fusion were recently reported in somatic soft tissue, brain, and kidney. However, such cases have not been identified in adult patients and the presence of a fusion between CIC, characteristic of CIC-rearranged sarcoma, and NUTM1-a defining feature of NC-poses a diagnostic challenge. We herein report a case of malignant epithelioid neoplasm with myoepithelial features harboring CIC-NUTM1 fusion arising in soft tissue of the head in a 60-year-old man. Immunohistochemistry revealed strong expression of NUT, but only weak ETV4 staining and negativity for keratins, EMA, p40, CD99, and WT1. SMARCB1 expression was retained. Fluorescence in situ hybridization and targeted next-generation sequencing identified a CIC-NUTM1 fusion resulting from t(15;19)(q14;q13.2).
expression of NUT, but only weak ETV4 staining and negativity for keratins, EMA, p40, CD99, and WT1. SMARCB1 expression was retained. Fluorescence in situ hybridization and targeted next-generation sequencing identified a CIC-NUTM1 fusion resulting from t(15;19)(q14;q13.2).
In light of morphologic features that overlap with those of NC from typical anatomical sites we have seen previously, the tumor was best classified as falling within the NC spectrum rather than CIC-associated sarcoma. This case highlights the emerging diagnostic challenges generated by newly detected gene fusions of unknown clinical and biologic significance. Careful integration of cytogenetic, molecular, and immunohistochemical findings with morphologic appearances in the diagnostic workup of undifferentiated neoplasms is essential.
| INTRODUCTION
NUT carcinoma (NC), a very aggressive type of poorly differentiated carcinoma, shows a wide anatomic distribution and is most frequently found in the chest and head and neck region along the midline. This tumor occurs in both children and adults with a wide age distribution (range, 0.1-82 years), a median age of 22 years, and a slight female predominance.
1,2 NC is defined by NUTM1 rearrangements and roughly 75% of cases harbor BRD4-NUTM1 fusion resulting from t (15;19)(q14;p13.1). 3 The remaining cases harbor either BRD3-NUTM1 fusion resulting from t(15;19)(q14;p34.2), 4 NSD3-NUTM1 fusion resulting from t(8;15)(p12;q15), 5 ZNF532-NUT, 6 or NUTM1 fusion with an unknown partner gene.
CIC-rearranged round cell sarcoma, in contrast, is an aggressive tumor predominantly arising in somatic soft tissue of trunk and extremities in young adults with a mean age of 32 years (range, 6-81 years) and a slight male predominance. 7 The identification of characteristic CIC rearrangements in a subset of round cell tumors lacking EWSR1 rearrangement in recent years led to the recognition of CICrearranged sarcomas as a distinct entity, separate from Ewing sarcoma. [7] [8] [9] Most cases harbor CIC-DUX4 fusion resulting from either t(4;19) or t(10;19). 7-9 CIC fusion genes (such as CIC-LEUTX) may also be seen in angiosarcoma, and CIC aberrations have been reported in oligodendroglioma, medulloblastoma, breast cancer, and others. 10, 11 Recently, cases of pediatric round cell tumors harboring CIC-NUTM1 fusions were identified in somatic soft tissue (N = 3, 2/3 in the head), 12 brain (N = 2), 13 or kidney (N = 1). 31 In addition, rare cases of round cell tumors located in somatic soft tissue, visceral locations, and brain were shown to harbor NUTM1 rearrangement with fusion partners other than CIC, including BRD4 (N = 3), BRD3, BCORL1, and MXD1 (one case each) fusions 14 -several of which had a myoepithelial-like appearance, and it is possible that these cases further expand the spectrum of NC.
We report herein a case of malignant epithelioid neoplasm with 
| Targeted next-generation sequencing
DNA extracted from FFPE tissue was subjected to targeted exon hybrid capture (Agilent, Santa Clara, CA) and next-generation sequencing using an Illumina HiSeq 2500 (Illumina, San Diego, CA).
The exonic sequences of 447 cancer-associated genes were interrogated for mutations and copy number variations, and 191 introns across 60 genes were examined for gene rearrangements, using our institution's targeted sequencing platform (OncoPanel). Bioinformatic detection of genomic aberrations is achieved using MuTect and GATK software for the detection of single nucleotide variants and small insertion-deletions, RobustCNV (an internally developed tool) for copy number analysis, and BreaKmer for large structural variations (details available upon request). maintenance immunotherapy with pembrolizumab given the concern for minimal residual disease. He is currently free of disease and without symptoms 10 months after resection.
| Morphology and Immunohistochemistry
The resection specimen consisted of an ill-defined solid mass extend- previously performed at the referring institution was negative. However, staining for CK7 was focally positive. Figure 3D ).
| Genetics

| DISCUSSION
We report herein the first case of malignant epithelioid neoplasm with an alternate CIC-NUTM1 fusion likely representing a novel variant of NC in somatic soft tissue of an adult patient. NC follows an aggressive clinical course, with median overall survival of 6.7 months. 1 Immunohistochemical staining for NUT has been shown to be highly specific for NC and is positive in the vast majority of cases, 17 resulting from NUTM1 fusions with either BRD4, BRD3, NSD3, ZNF532, or unknown partners. 6 As shown for the classic BRD4-NUTM1 fusion protein, the NUT portion of the oncogenic fusion protein binds to and activates a histone acetyl-transferase, p300, which is hypothesized to acetylate regional chromatin, recruiting more local BRD4-NUT and p300, leading to more local acetylation in a self-perpetuating manner. 18, 19 The creation by this process of large contiguous acetylated regions of chromatin enriched with BRD4-NUT and p300, called megadomains, 20 is thought to sequester p300 away from prodifferentiation genes. As a result, genes required for differentiation are repressed. Targeted therapies aim at reversing this feed-forward mechanism and enabling the tumor cells to differentiate. CIC-NUTM1 fusions are increasingly recognized in pediatric patients. 12, 31 The presence of a fusion between CIC-characteristic of (but by no means limited to) CIC-rearranged sarcoma-and NUTM1-a defining feature of NC-raises the question of whether to classify these neoplasms as sarcoma or carcinoma.
CIC-rearranged sarcomas behave in a clinically aggressive fashion,
show poor response to Ewing sarcoma chemotherapy regimens, and 5-year overall survival rates of only 43% compared to 76% for patients with Ewing sarcoma, highlighting the importance of recognizing these tumors as a distinct entity. 
